Search clinical trials for: ADC,

Total 399 results

University of Texas Southwestern Medical Center
National Institute on Aging (NIA)

Completed

Aerobic Exercise Training in Mild Cognitive Impairment Study (AETMCI)

Mild Cognitive Impairment

United States
Novartis Pharmaceuticals

Terminated

Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia

AML | cKIT-positive Solid Tumors

Belgium, Spain, Australia, Netherlands
ADC Therapeutics S.A.

Completed

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Puerto Rico
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

B-Cell Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin Lymphoma

United States, Spain, Italy, United Kingdom, Belgium, Czechia
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With Advanced Breast Cancer

Advanced Breast Cancer

China
ADC Therapeutics S.A.

Terminated

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Colo-rectal Cancer | Triple-negative Breast Cancer | Head and Neck Cancer Squamous Cell Carcinoma

United States, Belgium, United Kingdom
Centre Hospitalier Universitaire de Saint Etienne

Completed

Reproductibility of Lumbar Spine ADC Based on Different Post-processing Softwares (ADC)

Low Back Pain

France
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma

Taiwan, Korea, Republic of, United States, Brazil
ADC Therapeutics S.A.

Recruiting

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Spain, France
ADC Therapeutics S.A.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

Advanced Solid Tumors

United States, Spain, United Kingdom
Federal Research Institute of Pediatric Hematology...

Recruiting

DWI in the Diagnosis of Histological Types of Nephroblastoma in Children

Nephroblastoma (Wilms Tumour)

Russian Federation
Shanxi Province Cancer Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
Fudan University

Recruiting

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

China
RenJi Hospital

Recruiting

Combination of RC48 and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Upper Urinary Tract Urothelial Carcinoma | Kidney Preservation | HER-2 ADC | PD-1antibody

China
Alphamab (Australia) Co Pty Ltd.

Recruiting

First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Australia
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Metastatic Breast Cancer

China
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...

Completed

A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.

Refractory or Recurrent CD30+ Hematologic Malignancies

China
RemeGen Co., Ltd.

Completed

Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors

Solid Tumors

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

Solid Tumors

China
ADC Therapeutics S.A.

Withdrawn

Long-term Registry of Patients Treated With Loncastuximab Tesirine

B-Cell Lymphomas

United States
ADC Therapeutics S.A.

Withdrawn

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) (LOTIS-8)

Diffuse Large B-Cell Lymphoma

United States
ADC Therapeutics S.A.

Terminated

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

Spain, United States
ADC Therapeutics S.A.

Terminated

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Breast Cancer | Non Small Cell Lung Cancer | Bladder Cancer | GastroEsophageal Cancer

United States, Belgium
ADC Therapeutics S.A.

Terminated

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
Ambrx, Inc.

Withdrawn

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

HER2 Mutation-Related Tumors | HER2 Amplified Solid Tumors

United States
Heinrich Elinzano, MD
University of Texas; Rhode Island Hospital; Progenics Pharmaceuticals, Inc.

Completed

BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme | Gliosarcoma | GBM

United States
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Recruiting

A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors

Solid Tumor

China
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Recruiting

A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors

Solid Tumor

China
Tianjin Medical University Cancer Institute and...
Chongqing University Cancer Hospital; Xiangya Hospital of Central South University and other collaborators

Not yet recruiting

An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer

Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Muscle Invasive Bladder Carcinoma

China
Jiangsu Cancer Institute & Hospital

Not yet recruiting

RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2

Biliary Tract Cancer
RemeGen Co., Ltd.

Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Gastric Cancer

China
Chinese PLA General Hospital

Recruiting

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Advanced Gastroesophageal Adenocarcinoma

China
ADC Therapeutics S.A.

Recruiting

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

Japan, Belgium, France, Italy, Spain, United Kingdom, United States, Israel, Hungary, Brazil, Switzerland, Poland, Canada, Puerto Rico, Czechia, Netherlands, China, Mexico, Argentina, Chile, Turkey
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma

United States, Spain, United Kingdom, Poland, Belgium, Hungary, Germany, France, Italy, Czechia, Canada
ADC Therapeutics S.A.

Terminated

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

United States, Spain, United Kingdom, France, Italy, Belgium
ADC Therapeutics S.A.

Terminated

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United States, Belgium, Hungary, Israel, Spain, Switzerland, Poland, France, United Kingdom, Italy
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B-Cell Lymphoma Refractory

United States, United Kingdom, Italy, Switzerland
ADC Therapeutics S.A.

Terminated

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

Advanced Solid Tumors

United States
RenJi Hospital

Recruiting

RC48-ADC in HER2-low Advanced Breast Cancer

Advanced Breast Cancer

China
RemeGen Co., Ltd.

Not yet recruiting

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Non-small Cell Lung Cancer

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of KM501 in Patients With Solid Tumors

Advanced Solid Tumors

China
Alligator Bioscience AB

Completed

ADC-1013 First-in-Human Study

Neoplasms | Solid Tumors

United Kingdom, Denmark, Sweden
Shanghai Institute Of Biological Products
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

Advanced Solid Tumor
Jinling Hospital, China

Recruiting

A Study of RC48-ADC Combined With JS001 For Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma (1)

Carcinoma | Upper Tract Urothelial Carcinoma | UTUC

China
Memorial Sloan Kettering Cancer Center
Pfizer

Completed

Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma

Melanoma

United States
West China Hospital
RemeGen Co., Ltd.

Not yet recruiting

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer

China
TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

Hepatocellular Carcinoma | Advanced Solid Tumor

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer

Bladder Cancer

China
Peking University Cancer Hospital & Institute

Unknown

A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

China

Search clinical trials for: ADC,

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations